Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

bination with bendamustine and rituximab in R/R CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™-17, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment (a high unmet need population). The primary endpoint of the study is the overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company plans to complete enrollment for this study before year end 2013.
  • Phase III study of ibrutinib versus temsirolimus in R/R MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a monotherapy versus temsirolimus in R/R MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression-free-survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in patients with newly diagnosed MCL. The primary endpoint of the study is progression-free-survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with R/R MCL who progress after bortezomib therapy,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
    (Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
    (Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has ... Market by Product, Application, Technology, End User - Global ... The infectious disease diagnostics market is expected ... million by 2019 from $12,422.8 million in 2014. Increase ...
    Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
    ... 20 Pittsburgh -based Foundation Radiology Group ... proud to announce its strategic partnership with Acusis, a national provider ... , , , ... in Pittsburgh , Acusis delivers healthcare solutions that are designed ...
    ... 20 Medical Device Consultants, Inc. (MDCI), a ... the medical device and diagnostics industry, today announced a ... (CDSS), a clinical services and CRO based in ... to the best of both organizations, core strengths and ...
    Cached Medicine Technology:Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis 2Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis 3Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership 2Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership 3
    (Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
    (Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
    (Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
    (Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
    (Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
    Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... 11 WellPoint,s affiliated Life and Disability Companies are pleased ... designed to help new mothers adjust to their newborn baby ... Resources are available to all new and in-force short term ... New moms have access to Newborn and Parenting Resources once ...
    ... LONDON, November 11 Extensive research ... and University of,Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), ... CIRSE 2009 congress in Lisbon, Portugal. , ... last year, is,the world,s first patient specific system to ...
    ... ... in a free live broadcast. He will talk the audience through each step of the ... ... surgeon Dr Con Moshegov will undergo iLASIK procedure in a free live broadcast. He will ...
    ... ... surgeons in the Maryland specially trained to perform the latest minimally invasive single as well ... ... has joined Mercy Medical Center as the 135-year-old downtown hospital,s Medical Director of ...
    ... ... disciplines , ... CO (Vocus) November 11, 2009 -- HEALTHeCAREERS , North America’s premier healthcare Network, ... unemployment rate, the medical industry continues to be one of the few bright spots ...
    ... ... and adapt to new technologies and trends surrounding the endpoint. , ... Scottsdale, AZ (PRWEB) November 11, 2009 ... introduction of technologies like Web 2.0, consumer devices, virtualization and cloud computing onto the ...
    Cached Medicine News:Health News:WellPoint's Affiliated Life and Disability Companies Offer Newborn and Parenting Resources to Ease New Mothers' Transition Back to Work After Maternity Leave 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Eye Surgeon Broadcasts own Surgery 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Lumension Webinar Highlights the Evolving State of the Endpoint 2Health News:Lumension Webinar Highlights the Evolving State of the Endpoint 3
    ... synergy T-EP Developed in collaboration with ... and an exceptionally high standard of ... Multimedia technology and design expertise to ... 2, 5 or 10-channel Medelec Synergy ...
    Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
    The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
    ... the MYOHANDY family are probably the ... - SystemPLUS line. Based on last ... of the ISA 100x EP series ... 1002 EP) , 4 channels (ISA ...
    Medicine Products: